Hereditary Angioedema Market
Hereditary Angioedema Market Size, Share and Trends Analysis Report, By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), By Route of Administration (Intravenous, Subcutaneous Injection, and Oral) Forecast Period, (2026-2035)
Industry Overview
Hereditary Angioedema market was valued at $3,512 million in 2025 and is projected to reach $8,421.29 million by 2035, growing at a CAGR of 9.2% during the forecast period (2026-2035). The hereditary angioedema therapeutics market is expanding due to rising disease awareness and improved diagnostic pathways across healthcare systems. Advancements in targeted biologics and oral kallikrein inhibitors are strengthening treatment adoption among both acute and prophylactic patient groups. Increasing regulatory approvals and strong clinical trial activity are contributing to a broader therapeutic landscape. Healthcare providers are placing greater emphasis on self-administration options, which supports demand for subcutaneous and oral therapies. Strategic collaborations among biopharmaceutical companies and ongoing innovation in rare disease research continue to reinforce long-term market development.
Market Dynamics
Advancements in targeted therapies and expanding treatment options
The hereditary angioedema market is supported by continuous progress in targeted drug development focused on the bradykinin pathway and plasma kallikrein inhibition. The introduction of long-acting prophylactic therapies has shifted clinical practice toward preventive care, improving patient adherence and physician confidence in sustained treatment regimens. Oral formulations and self-administered subcutaneous injections are reducing reliance on hospital-based infusions, which enhances accessibility across diverse care settings. Strong clinical evidence demonstrating reduced attack frequency and improved quality of life is encouraging earlier treatment initiation. Pharmaceutical companies are investing in next-generation biologics and small-molecule inhibitors, strengthening product pipelines and lifecycle management strategies. Regulatory agencies are granting approvals for innovative therapies addressing rare disease needs, which supports steady commercialization activity. Expansion of clinical trial programs is also improving understanding of disease subtypes, enabling more precise therapeutic positioning.
Rising diagnosis rates and improved rare disease management frameworks
Greater awareness among healthcare professionals and patient advocacy groups is leading to earlier identification of hereditary angioedema, supporting sustained demand for effective therapies. Advancements in genetic testing and diagnostic protocols are reducing misdiagnosis of allergic or inflammatory conditions, which enhances treatment accuracy. Healthcare systems are increasingly prioritizing rare disease management through reimbursement support and structured treatment guidelines. Educational initiatives aimed at emergency physicians and immunologists are improving recognition of acute attacks, encouraging appropriate therapeutic use. Expansion of specialty care centers and telemedicine consultations is improving patient access to expert management, particularly for long-term prophylaxis. Real-world evidence studies are reinforcing confidence in modern treatment outcomes, influencing prescribing patterns. Strategic collaborations between research institutions and biopharmaceutical companies are further accelerating innovation aligned with unmet clinical needs.
Market Segmentation
- Based on the drug class, the market is segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others.
- Based on the route of administration, the market is segmented into Intravenous, Subcutaneous Injection, and Oral.
Established Backbone of HAE Therapy
C1 esterase inhibitor therapies represent a leading share within the drug class segment, supported by long-standing clinical adoption in both acute management and prophylaxis. Strong physician familiarity and extensive safety data continue to sustain prescribing confidence across specialist centers. Key companies such as Takeda Pharmaceutical Company, CSL Limited, and Pharming Group maintain a significant presence through plasma-derived and recombinant formulations. Ongoing product enhancements focus on improving dosing convenience and reducing infusion frequency. Regulatory approvals for expanded indications have reinforced the segment’s commercial stability. Real-world evidence highlighting consistent attack prevention remains a primary growth catalyst.
Shift Toward Convenient Oral Therapies
Oral administration is emerging as a rapidly expanding route of delivery, driven by patient preference for non-injectable prophylactic options. The introduction of oral kallikrein inhibitors has changed treatment dynamics by enabling home-based long-term management. BioCryst Pharmaceuticals and KalVista Pharmaceuticals are advancing oral pipeline candidates aimed at improving adherence and reducing healthcare visits. Clinical development efforts emphasize sustained efficacy with simplified dosing schedules, reflecting a broader shift toward patient-centric care models. Recent trials highlight strong uptake potential among newly diagnosed individuals seeking convenient therapy formats. Increasing investment in oral small-molecule research continues to shape future competitive positioning within this segment.
Regional Outlook
The global hereditary angioedema market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Strong Innovation Momentum in North America
North America continues to show steady progress in hereditary angioedema treatment adoption, supported by structured rare disease reimbursement pathways and established specialty care networks. The presence of major developers such as Takeda Pharmaceutical Company and BioCryst Pharmaceuticals contributes to active product launches and lifecycle expansions. Increased uptake of long-term prophylactic therapies reflects physician preference for preventive disease management. Regulatory support for orphan drugs is encouraging ongoing clinical development and label extensions. Expansion of home-based treatment models is improving patient adherence and reducing hospital dependency. Partnerships between research centers and industry participants continue to strengthen innovation within the region.
Evolving Treatment Landscape across Europe
Europe is experiencing a gradual expansion driven by improved diagnosis rates and coordinated rare disease policies across major healthcare systems. Companies, including CSL Limited and Pharming Group, maintain a visible footprint through established biologic therapies and pipeline development. Growing acceptance of subcutaneous and oral options reflects a shift toward patient-friendly administration routes. National reimbursement frameworks are supporting broader access to advanced prophylactic treatments. Increased participation in multinational clinical trials is accelerating therapy availability across key markets. Continued emphasis on guideline-based care is shaping prescribing patterns and sustaining regional demand.
Market Players Outlook
The major companies operating in the global hereditary angioedema market include Takeda Pharmaceutical Company Ltd, CSL Limited (CSL Behring), Pharming Group N.V., BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In January 2026, Ionis Pharmaceuticals received European authorization for DAWNZERA (donidalorsen), marking the first RNA-targeted therapy approved for hereditary angioedema prevention, reflecting a shift toward advanced genetic-based treatment approaches.
- In January 2025, FDA approvals expanded therapeutic access, including oral prophylactic therapy berotralstat pellets for pediatric patients, strengthening the oral treatment segment.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global hereditary angioedema Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Hereditary Angioedema Market Sales Analysis – Drug Class | Route of Administration ($ Million)
- Hereditary Angioedema Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Hereditary Angioedema Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Hereditary Angioedema Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Hereditary Angioedema Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Hereditary Angioedema Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Hereditary Angioedema Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Hereditary Angioedema Market Revenue and Share by Manufacturers
- Hereditary Angioedema Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Takeda Pharmaceutical Company Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- CSL Ltd. (CSL Behring)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pharming Group N.V.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- BioCryst Pharmaceuticals, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- KalVista Pharmaceuticals, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Takeda Pharmaceutical Company Ltd.
- Key Company Analysis
- Global Hereditary Angioedema Market Sales Analysis by Drug Class ($ Million)
- C1 Esterase Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
- Others
- Global Hereditary Angioedema Market Sales Analysis by Route of Administration ($ Million)
- Intravenous
- Subcutaneous Injection
- Oral
- Regional Analysis
- North American Hereditary Angioedema Market Sales Analysis – Drug Class | Route of Administration | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Hereditary Angioedema Market Sales Analysis – Drug Class | Route of Administration | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Hereditary Angioedema Market Sales Analysis – Drug Class | Route of Administration | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Hereditary Angioedema Market Sales Analysis – Drug Class | Route of Administration | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Adverum Biotechnologies, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Arrowhead Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca PLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Astria Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Attune Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BioMarin Pharmaceutical Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CENTOGENE N.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Grifols S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ionis Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pharvaris N.V.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Regeneron Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche Holding AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Swedish Orphan Biovitrum AB (Sobi)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Adverum Biotechnologies, Inc.
1. Global Hereditary Angioedema Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global C1 Esterase Inhibitor Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Selective Bradykinin B2 Receptor Antagonist Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Kallikrein Inhibitor Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Others Drug Class Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Hereditary Angioedema Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
7. Global Intravenous Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Subcutaneous Injection Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Oral Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
11. North American Hereditary Angioedema Market Research and Analysis by Country, 2025–2035 ($ Million)
12. North American Hereditary Angioedema Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
13. North American Hereditary Angioedema Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
14. European Hereditary Angioedema Market Research and Analysis by Country, 2025–2035 ($ Million)
15. European Hereditary Angioedema Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
16. European Hereditary Angioedema Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
17. Asia-Pacific Hereditary Angioedema Market Research and Analysis by Country, 2025–2035 ($ Million)
18. Asia-Pacific Hereditary Angioedema Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
19. Asia-Pacific Hereditary Angioedema Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
20. Rest of the World Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
21. Rest of the World Hereditary Angioedema Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
22. Rest of the World Hereditary Angioedema Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)
1. Global Hereditary Angioedema Market Share by Illumination Type, 2025 vs 2035 (%)
2. Global Laser Phosphor Projection Market Share by Region, 2025 vs 2035 (%)
3. Global RGB Hereditary Angioedema Market Share by Region, 2025 vs 2035 (%)
4. Global Laser Diode Projection Market Share by Region, 2025 vs 2035 (%)
5. Global Hybrid Illumination Projection Market Share by Region, 2025 vs 2035 (%)
6. Global Hereditary Angioedema Market Share by Resolution, 2025 vs 2035 (%)
7. Global XGA Hereditary Angioedema Market Share by Region, 2025 vs 2035 (%)
8. Global WXGA Hereditary Angioedema Market Share by Region, 2025 vs 2035 (%)
9. Global HD Hereditary Angioedema Market Share by Region, 2025 vs 2035 (%)
10. Global 4K Hereditary Angioedema Market Share by Region, 2025 vs 2035 (%)
11. Global Others Resolution Hereditary Angioedema Market Share by Region, 2025 vs 2035 (%)
12. Global Hereditary Angioedema Market Share by End-Users, 2025 vs 2035 (%)
13. Global Hereditary Angioedema in Education Market Share by Region, 2025 vs 2035 (%)
14. Global Hereditary Angioedema in Enterprises Market Share by Region, 2025 vs 2035 (%)
15. Global Hereditary Angioedema in Media & Entertainment Market Share by Region, 2025 vs 2035 (%)
16. Global Hereditary Angioedema in Retail Market Share by Region, 2025 vs 2035 (%)
17. Global Hereditary Angioedema in Others End-Users Market Share by Region, 2025 vs 2035 (%)
18. Global Hereditary Angioedema Market Research and Analysis by Region, 2025–2035 ($ Million)
19. US Hereditary Angioedema Market Size, 2025–2035 ($ Million)
20. Canada Hereditary Angioedema Market Size, 2025–2035 ($ Million)
21. UK Hereditary Angioedema Market Size, 2025–2035 ($ Million)
22. France Hereditary Angioedema Market Size, 2025–2035 ($ Million)
23. Germany Hereditary Angioedema Market Size, 2025–2035 ($ Million)
24. Italy Hereditary Angioedema Market Size, 2025–2035 ($ Million)
25. Spain Hereditary Angioedema Market Size, 2025–2035 ($ Million)
26. Russia Hereditary Angioedema Market Size, 2025–2035 ($ Million)
27. Rest of Europe Hereditary Angioedema Market Size, 2025–2035 ($ Million)
28. India Hereditary Angioedema Market Size, 2025–2035 ($ Million)
29. China Hereditary Angioedema Market Size, 2025–2035 ($ Million)
30. Japan Hereditary Angioedema Market Size, 2025–2035 ($ Million)
31. South Korea Hereditary Angioedema Market Size, 2025–2035 ($ Million)
32. Australia and New Zealand Hereditary Angioedema Market Size, 2025–2035 ($ Million)
33. ASEAN Economies Hereditary Angioedema Market Size, 2025–2035 ($ Million)
34. Rest of Asia-Pacific Hereditary Angioedema Market Size, 2025–2035 ($ Million)
35. Latin America Hereditary Angioedema Market Size, 2025–2035 ($ Million)
36. Middle East and Africa Hereditary Angioedema Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Hereditary Angioedema Market in 2025 is estimated to be around $3,512 million.
North America holds the largest share in the Hereditary Angioedema Market.
Leading players in the Hereditary Angioedema Market include Takeda Pharmaceutical Company Ltd, CSL Limited (CSL Behring), Pharming Group N.V., BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., among others.
The Hereditary Angioedema Market is expected to grow at a CAGR of 9.2% from 2026 to 2035.
The Hereditary Angioedema Market growth is driven by increasing diagnosis of rare genetic disorders and rising availability of targeted prophylactic and on-demand therapeutic treatments.
